Citi says Lupin-Astellas settlement may delay rival generic launches

Astellas Pharma

10/02/2026 06:13

** Citi Research says Lupin's LUPN.NS $90 million patent settlement with Astellas Pharma 4503.T may prevent other generic drugmakers from launching generic Mirabegron for an extended period, potentially giving Lupin and Zydus Lifesciences ZYDU.NS about 12–18 months of limited competition

** Settlement allows Lupin to continue selling its generic version of Mirabegron, a bladder disorder drug, eliminating legal risks associated with prolonged litigation - Citi

** Citi maintains "buy" on LUPN at PT 2260 rupees

** Stock rated "buy" on avg by 35 analysts; median PT 2350 rupees - data compiled by LSEG

** Stock up 5% YTD; last up 1% at 2218 rupees

 (Reporting by Aleef Jahan in Bengaluru)

 ((aleefjahan.cs@thomsonreuters.com))